Although previous clinical trials combining anti-PD-L1 therapy with CAR-T in lymphoma demonstrated no benefit for the combination approach66, our study provided early evidence of anti-tumor activity of tebotelimab monotherapy in R/R DLBCL, including those patients previously treated with CAR-T. The gene discussed is CD274; the disease is neoplasm.